Changzhou Qianhong Biopharma Co Ltd - Asset Resilience Ratio
Changzhou Qianhong Biopharma Co Ltd (002550) has an Asset Resilience Ratio of 18.70% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002550 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Changzhou Qianhong Biopharma Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Changzhou Qianhong Biopharma Co Ltd assets under control.
Liquid Assets Composition Over Time
This chart breaks down Changzhou Qianhong Biopharma Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Changzhou Qianhong Biopharma Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥604.36 Million | 18.7% |
| Total Liquid Assets | CN¥604.36 Million | 18.70% |
Asset Resilience Insights
- Good Liquidity Position: Changzhou Qianhong Biopharma Co Ltd maintains a healthy 18.70% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Changzhou Qianhong Biopharma Co Ltd Industry Peers by Asset Resilience Ratio
Compare Changzhou Qianhong Biopharma Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Changzhou Qianhong Biopharma Co Ltd (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Changzhou Qianhong Biopharma Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.24% | CN¥594.02 Million ≈ $86.92 Million |
CN¥3.09 Billion ≈ $451.70 Million |
+9.57pp |
| 2024-12-31 | 9.67% | CN¥273.83 Million ≈ $40.07 Million |
CN¥2.83 Billion ≈ $414.18 Million |
+4.72pp |
| 2023-12-31 | 4.95% | CN¥136.93 Million ≈ $20.04 Million |
CN¥2.77 Billion ≈ $404.76 Million |
+2.55pp |
| 2022-12-31 | 2.40% | CN¥67.48 Million ≈ $9.87 Million |
CN¥2.81 Billion ≈ $410.60 Million |
-0.32pp |
| 2021-12-31 | 2.72% | CN¥68.23 Million ≈ $9.98 Million |
CN¥2.51 Billion ≈ $367.06 Million |
-6.84pp |
| 2020-12-31 | 9.56% | CN¥234.28 Million ≈ $34.28 Million |
CN¥2.45 Billion ≈ $358.77 Million |
-13.04pp |
| 2019-12-31 | 22.59% | CN¥662.98 Million ≈ $97.01 Million |
CN¥2.93 Billion ≈ $429.38 Million |
-19.09pp |
| 2018-12-31 | 41.69% | CN¥1.32 Billion ≈ $193.89 Million |
CN¥3.18 Billion ≈ $465.09 Million |
-10.30pp |
| 2017-12-31 | 51.99% | CN¥1.58 Billion ≈ $231.61 Million |
CN¥3.04 Billion ≈ $445.48 Million |
-- |
| 2016-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥3.03 Billion ≈ $443.95 Million |
-- |
| 2015-12-31 | 0.36% | CN¥10.25 Million ≈ $1.50 Million |
CN¥2.83 Billion ≈ $414.58 Million |
-0.08pp |
| 2014-12-31 | 0.44% | CN¥10.23 Million ≈ $1.50 Million |
CN¥2.31 Billion ≈ $338.13 Million |
+0.43pp |
| 2013-12-31 | 0.02% | CN¥362.70K ≈ $53.07K |
CN¥2.07 Billion ≈ $302.36 Million |
0.00pp |
| 2012-12-31 | 0.02% | CN¥338.65K ≈ $49.56K |
CN¥1.93 Billion ≈ $282.04 Million |
0.00pp |
| 2011-12-31 | 0.02% | CN¥369.85K ≈ $54.12K |
CN¥1.85 Billion ≈ $271.18 Million |
-0.06pp |
| 2010-12-31 | 0.08% | CN¥431.60K ≈ $63.16K |
CN¥548.53 Million ≈ $80.27 Million |
-0.01pp |
| 2009-12-31 | 0.09% | CN¥464.10K ≈ $67.91K |
CN¥533.87 Million ≈ $78.12 Million |
0.00pp |
| 2008-12-31 | 0.09% | CN¥353.60K ≈ $51.74K |
CN¥391.74 Million ≈ $57.32 Million |
-0.15pp |
| 2007-12-31 | 0.24% | CN¥683.80K ≈ $100.06K |
CN¥288.56 Million ≈ $42.23 Million |
-- |
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more